GFI1 and fungal infectious disease: Those strategies include genetic manipulation (Gfi-1-/- knockout) [20] or the implementation of monoclonal antibodies such as anti-Gr1 (RB6-8C5) or anti-Ly6G (1A8) in animal models inducing depletion of neutrophils [21], the latter being most widely used to evaluate the in vivo functions of these cells during the development of immune response against infections caused by Toxoplasma gondii [22], Leishmania amazonensis [23], and fungal infections caused by Aspergillus fumigatus [24], Cryptococcus neoformans [25,26] and Candida albicans [27].